NEW YORK, June 3, 2026, 18:05 (EDT)
Cytek Biosciences was trading lower Wednesday. Shares last changed hands at $4.05, off 16 cents, down roughly 3.8%. Market cap stood at about $521 million. Around 706,600 shares moved.
Investors got more company news to process. Cytek Biosciences plans to unveil a 7-laser cell-analysis system at CYTO 2026, and a new filing said Philippe Busque, senior VP for global sales and services, is set to exit on June 5 for another job. The company said Busque’s exit isn’t tied to any dispute over operations, policies, or practices.
CYTO 2026 kicks off June 6 in West Palm Beach, Florida. Cytek shows up hoping its latest instruments can give sales a push, with the company still trying to find traction after a tough first quarter in the red. The timing is close for a turnaround pitch to this crowd.
Cytek said its Borealis platform will launch first in an early access program, limiting availability until a wider commercial release. The machine features 120 detectors over seven laser lines, with deep UV and IR lasers included, designed for 60-color panels that allow more cell markers to be read from a single sample.
Flow cytometry is a way to measure cell properties by reading light signals as the cells move through a device. Cytek CEO Wenbin Jiang said the company’s new products are designed to help researchers “generate deeper insights from one sample with greater efficiency and confidence.” BioSpace
The stock lagged behind the broader biotech sector. The SPDR S&P Biotech ETF gained roughly 1.6%. The iShares Russell 2000 Index Fund, which tracks small caps, dropped around 1.4%.
Cytek posted Q1 revenue of $44.1 million, up 6% year over year, but the net loss grew to $18.9 million from $11.4 million. The company kept its 2026 revenue guidance unchanged at $205 million to $212 million, which would be growth of 2% to 5%.
Recurring revenue made up 35% of total revenue in the first quarter on a trailing 12-month view, up from 31% for the same period last year. The increase points to more repeat sales coming from services and reagents. Instrument placements can drive later sales of consumables and service contracts.
Cytek is up against a long list of competitors. Its annual filing names Beckman Coulter, which is owned by Danaher, Standard BioTools, and Thermo Fisher Scientific as direct rivals, all looking for a share of lab budgets in cell analysis and life sciences tools.
Borealis and the new dyes are only in early access for now, so the product news may not mean revenue soon. Cytek plans a wider launch later, but risk factors in its own disclosures include slow customer adoption, tariffs, export controls, and scaling up manufacturing, all of which could affect results.
Cytek gets some time in the spotlight this week. The real test is whether a pricier system, some new faces in sales, and losses on the bottom line will come together quickly enough for investors, who keep pushing the stock down.
